States. It was the 25th biosimilar to be approved by the FDA. In February 2020, the biosimilar Amsparity was approved for use in the European Union. In June 2020, the biosimilar Idacio was approved for use in Australia. In July 2020, adalimumab-fkjp (Hulio) was approved for use in the United States. In August 2020, the biosimilar Cadalimab was launched in India by Cadila Pharmaceuticals. Idacio was approved for medical use in Canada in October 2020. In November 2020, Amgevita, Hulio, and Hyrimoz were approved for medical use in Canada. On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yuflyma, intended for the treatment of certain inflammatory and autoimmune disorders. The applicant for this medicinal product is Celltrion Healthcare Hungary Kft. It was approved for medical use in the European Union in February 2021. In January 2021, Abrilada was approved for medical use in Canada. On 16 September 2021, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal products Libmyris and Hukyndra, intended for the treatment of certain inflammatory and autoimmune disorders. The applicant for these medicinal products is Stada Arzneimittel. The biosimilars Libmyris and Hukyndra were approved for medical use in the European Union in November 2021. In December 2021, adalimumab-aqvh (Yusimry) was approved for medical use in the United States. In December 2021, Yuflyma was approved for medical use in Canada. In January 2022, Simlandi was approved for medical use in Canada. Adalimumab-aacf (Idacio) was approved for medical use in the United States in December 2022. In January 2023, the CHMP recommended that the high-concentration 100mg/ml Hyrimoz biosimilar be granted a pan-European marketing authorization for all indications covered by the reference medicine, including Crohn's disease, plaque psoriasis, ulcerative colitis, rheumatoid arthritis and uveitis. Royalty litigation In March 2003, Cambridge Antibody Technology (CAT) stated its wish to "initiate discussions regarding the applicability of the royalty offset provisions for Humira" with Abbott Laboratories in the High Court of London. In November 2004, the trial began, and in December 2004, Justice Hugh Laddie ruled for CAT. A short version of the full statement of the proceedings was released. In it Justice Laddie remarked, "Abbott was in error when it made its first royalty payment to CAT calculated on the basis